Human Muscle Gene Expression Profiles in Young and Old Men (CERA)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To reach the goals of living longer in better medical conditions, many countries reach the same conclusion: new strategies have to be developed to avoid, or at least limit, the effects of age; this requires a better knowledge of the mechanisms of aging. Our project focuses on the loss of muscle mass associated with aging, called sarcopenia. Sarcopenia unavoidably leads to impaired mobility and poor balance, which contributes to loss of functional autonomy and to increased prevalence for severe falls. Skeletal muscle also plays a central role as a reserve for energy and amino acids. Hence, sarcopenia further triggers severe side metabolic effects such as frailty among elderly persons. The precise mechanisms of muscle aging are still mostly unknown, although many theories have been proposed.
The present study aims at better understanding the mechanisms of skeletal muscle loss associated with aging. Using muscle biopsies from young and old subjects, the differential expression profiles of mRNA will be obtained through chips that will evaluate more than 39000 transcripts. On the same samples, proteomic analyses will involve two complementary approaches: (1) bidimensional electrophoresis (2DGE) coupled to mass spectrometry (MALDI-ToF) for dominant proteins; (2) Western-blot (more than 800 antibodies) targeting regulating proteins not detectable using 2DGE. Complementary histological studies (immunohisto-fluorescence, confocal microscopy) will specify the localisation of the major biomarkers in the muscle biopsies.
The results of that research will have applications in the medium term and will lead to nutritional interventions to modulate specific metabolic pathways and improve the quality of life in the elderly.
| Condition | Intervention |
|---|---|
|
Elderly Sarcopenia |
Other: Skeletal muscle aging |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Human Muscle Gene Expression Profiles in Young and Old Men |
- To identify the differential expression profiles (proteomics, transcriptomics) in skeletal muscle between young and old men [ Time Frame: During biopsie (W3) ] [ Designated as safety issue: No ]
- To specify the localisation of the major biomarkers in the muscle biopsies. [ Time Frame: During biopsie (W3) ] [ Designated as safety issue: No ]
- To compare muscular energy metabolic enzymatic activities between young and old men [ Time Frame: during biopsie (W3) ] [ Designated as safety issue: No ]
- To compare the number of muscular stem cells between young and old men [ Time Frame: during biopsie (W3) ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples With DNA
Serum, muscle
| Enrollment: | 41 |
| Study Start Date: | October 2008 |
| Study Completion Date: | March 2009 |
| Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Young
Young men 19-25 years old
|
Other: Skeletal muscle aging
W1 - Blood test
W2 - Maximal metabolic test using a cycloergometer W3 - Muscular biopsy |
|
Old
old men 70-76 years old, who participate in the PROOF study (NCT 00759304)
|
Other: Skeletal muscle aging
W1 - Blood test
W2 - Maximal metabolic test using a cycloergometer W3 - Muscular biopsy |
Eligibility| Ages Eligible for Study: | 19 Years to 76 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Young : students of the Saint-Etienne's university. Old : men who participate in the PROOF study
Inclusion Criteria:
- Affiliated or beneficiary of a social security category
- Having signed the inform consent form
- Having signed the genetic consent form
Exclusion Criteria:
- Antiaggregant platelet treatment
- Type 2 diabetes
- Body Mass Index > 25
- Severe renal disease
- CRP > 10
- Abnormal clotting test
- Allergies to local anesthetics
Contacts and Locations| France | |
| CHU de Saint-Etienne | |
| Saint-etienne, France, 42000 | |
| Study Chair: | Daniel BECHET, PhD | INRA Clermont-Ferrand |
| Principal Investigator: | Jean-Claude BARTHELEMY, MD PhD | CHU de Saint-Etienne |
More Information
No publications provided
| Responsible Party: | Clément CAILLAUX, CHU de Saint-Etienne |
| ClinicalTrials.gov Identifier: | NCT00725166 History of Changes |
| Other Study ID Numbers: | 0708102, 2008-A00374-51 |
| Study First Received: | July 29, 2008 |
| Last Updated: | June 9, 2009 |
| Health Authority: | France: Ministry of Health France: Direction Générale de la Santé France: French Data Protection Authority |
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne:
|
Aging Biopsy Skeletal muscle Molecular biology |
Genetic markers Gene expression regulation Young and old men Healthy volunteers |
Additional relevant MeSH terms:
|
Sarcopenia Muscular Atrophy Neuromuscular Manifestations Neurologic Manifestations |
Nervous System Diseases Atrophy Pathological Conditions, Anatomical Signs and Symptoms |
ClinicalTrials.gov processed this record on May 19, 2013